ClinicalTrials.gg
CompletedNCT02424344ACTIVATEUpdated Oct 9, 2018Results posted

Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients

A Phase 4 interventional study of Aclidinium/Formoterol and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by AstraZeneca. Completed at 26 sites in 4 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-10-09.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
40 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing aclidinium in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. aclidinium · Pulmonary Disease, Chronic Obstructive.

Enrollment
19th of 31
267 · median 414
Started
2015
with 1 other
Phase 4
8 of 32
none open now
Registered
28th of 32
by date
Lead sponsor
28 of 32
AstraZeneca

Among the 32 studies testing aclidinium in Pulmonary Disease, Chronic Obstructive, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 4, and was the 28th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 32 studies testing aclidinium in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About aclidinium

aclidinium: first FDA approval 2012 (TUDORZA PRESSAIR), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 32 studies testing aclidinium in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The present study is planned to evaluate the effect of the aclidinium bromide/formoterol fumarate 400/12 μg FDC BID on the hyperinflation, exercise endurance and physical activity in patients with moderate to severe COPD. Additionally, the effect of the behavioural intervention on top of aclidinium bromide/formoterol fumarate 400/12 μg will be assessed both on the exercise endurance and the physical activity.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and non-pregnant, non-lactating females aged ≥ 40.
  2. Patients with a clinical diagnosis of according to GOLD guidelines 2014, with a post bronchodilator ≥ 40% and \< 80% of the predicted value and FEV1/FVC \< 70% at Visit 1.
  3. Functional residual capacity (FRC) measured by body plethysmography at Visit 1 ≥ 120% of predicted value.
  4. Patients with modified Medical Research Council dyspnea scale (mMRC) ≥ 2 at Visit 1.
  5. Current or former cigarette smokers with a smoking history of at least 10 pack-years at Visit 1
  6. Patients willing to participate in the telecoaching program during the four last weeks and to enhance their physical activity
  7. Patients who understand and are able to follow the study procedures, are cooperative and are willing to participate in the study as indicated by signing the .

Exclusion criteria

Exclusion Criteria:

  1. History or current diagnosis of asthma.
  2. Any respiratory tract infection (including upper respiratory tract) or exacerbation in the 6 weeks prior to Visit 1 or during the run-in period.
  3. Patients who have been hospitalised for an acute COPD exacerbation within 3 months prior to Visit 1 or during the run-in period.
  4. respiratory conditions other than COPD.
  5. Use of long-term oxygen therapy (≥ 15 hours/day).
  6. Oxygen saturation ≤ 85% as measured by pulse oximetry during exercise testing at Visit 1, Visit 2 or Visit 3 prior to randomisation.
  7. Patients with a (BMI) ≥ 40kg/m2.
  8. Patient who may need to start a pulmonary rehabilitation program during the study and/or who started/finished it within 3 months prior to Visit 1 or during the run-in period.
  9. Patients with clinically significant cardiovascular conditions.
  10. Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension.
  11. Patient with known non-controlled history of infection with (HIV) and/or active hepatitis.
  12. Patients with clinically relevant abnormalities in the results of the blood pressure, , or physical examination at Visit 1.
  13. Patients with any serious or uncontrolled physical or mental dysfunction that could place the patient at higher risk derived from his/her participation in the study or could confound the results
  14. Patients with conditions other than COPD that may contribute to dyspnoea and exercise limitation or with to clinical exercise testing according to ATS recommendations for CPET
  15. Patients with other relevant comorbidities that make the patient nor suitable to follow-up study procedures and/or could affect physical activity
  16. Patients who cycled \< 2 minutes or > 15 minutes during the constant work-rate exercise tests conducted at Visit 2 (Run-in Visit) or at Visit 3 even after adjustment of the work load.
  17. Patients with history of reaction to inhaled anticholinergics, sympathomimetic amines or inhaled medication or any component thereof (including report of paradoxical bronchospasm)
  18. Patients for whom the use of anticholinergic drugs is contraindicated (acute urinary retention, symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma)
  19. Patients unable to properly use a multidose dry powder inhaler or a pressurized metered-dose inhaler (pMDI).
  20. Patients using any prohibited medication (including IMP within 30 days (or 6 half-lives, whichever is longer) before Visit 1) or who have not undergone the required .
  21. History of of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer).
  22. Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers, sleep apnea).
  23. Patients unable to give their consent, or patients of consenting age but under guardianship, or vulnerable patients
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg

    8 weeks, double blind treatment period

    Drug: Aclidinium/Formoterol

  • Placebo comparator
    Placebo to Aclidinium/Formoterol

    8 weeks, double blind treatment period

    Drug: Placebo

Interventions

  • DrugAclidinium/Formoterol

    Drug pages: Aclidinium · Formoterol

    Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler

  • DrugPlacebo

    Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough Functional Residual Capacity (FRC) After 4 Weeks of Treatment

    Baseline values in FRC were defined as the corresponding values just before randomization on Day 1 of treatment (Week 0). Trough values were obtained prior to study drug administration.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Change From Baseline in Endurance Time (ET) During Constant Work Rate Cycle Ergometry at Week 8

    The ET was the time from the increase in work rate to 75% Wmax to the point of symptom limitation. Baseline measurements were taken prior to the IP dose on Day 1. Measurements at Week 8 were taken at 3 hours post-dose. Participants underwent a behavioural intervention (consisting of a telecoaching programme to enhance physical activity) between Week 4 and Week 8.

    Time frame: Baseline to Week 8

  2. Percentage of Inactive Patients (Mean of <6000 Steps Per Day) at Week 8

    Physical activity was assessed by means of measurement of activity parameters (e.g. number of steps) through a Dynaport MoveMonitor and completion of the Daily ProActive Physical Activity in chronic obstructive pulmonary disease (COPD) questionnaire. Compliant criterion based on at least 8 hours per day, and at least 3 days per week. Participants underwent a behavioural intervention (consisting of a telecoaching programme to enhance physical activity) between Week 4 and Week 8. Baseline was defined as mean of steps/day assessed during the week before the randomisation visit.

    Time frame: Week 8

07

Results

Posted Oct 9, 2018

Participant flow

This study was conducted at 26 study centers, 15 in Germany, 4 in Hungary, 3 in Spain and 4 in Canada. The first patient was enrolled in April 2015 and the last patient visit was in July 2016.

Participant flow — Overall Study
MilestoneAB/FF 400/12 μgPlacebo
Started134133
Completed127123
Not completed710
Withdrew: Lack of efficacy01
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up10
Withdrew: Adverse event48

Outcome measures

PrimaryChange From Baseline in Trough Functional Residual Capacity (FRC) After 4 Weeks of Treatment

Baseline values in FRC were defined as the corresponding values just before randomization on Day 1 of treatment (Week 0). Trough values were obtained prior to study drug administration.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · Liters
Change From Baseline in Trough Functional Residual Capacity (FRC) After 4 Weeks of Treatment
LitersAB/FF 400/12 μgPlacebo
Change From Baseline in Trough Functional Residual Capacity (FRC) After 4 Weeks of Treatment-0.162 ± 0.050-0.037 ± 0.050
Statistical analysis
  • AB/FF 400/12 μg vs Placebo · ANCOVA · p = 0.069 · Least square mean difference: -0.125 · 95% CI -0.259 to 0.010Adjusted by baseline and age as covariates, and treatment group, sex and smoking-status as fixed effect factors
SecondaryChange From Baseline in Endurance Time (ET) During Constant Work Rate Cycle Ergometry at Week 8

The ET was the time from the increase in work rate to 75% Wmax to the point of symptom limitation. Baseline measurements were taken prior to the IP dose on Day 1. Measurements at Week 8 were taken at 3 hours post-dose. Participants underwent a behavioural intervention (consisting of a telecoaching programme to enhance physical activity) between Week 4 and Week 8.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · Seconds
Change From Baseline in Endurance Time (ET) During Constant Work Rate Cycle Ergometry at Week 8
SecondsAB/FF 400/12 μgPlacebo
Change From Baseline in Endurance Time (ET) During Constant Work Rate Cycle Ergometry at Week 850.7 ± 18.1-4.6 ± 18.2
SecondaryPercentage of Inactive Patients (Mean of <6000 Steps Per Day) at Week 8

Physical activity was assessed by means of measurement of activity parameters (e.g. number of steps) through a Dynaport MoveMonitor and completion of the Daily ProActive Physical Activity in chronic obstructive pulmonary disease (COPD) questionnaire. Compliant criterion based on at least 8 hours per day, and at least 3 days per week. Participants underwent a behavioural intervention (consisting of a telecoaching programme to enhance physical activity) between Week 4 and Week 8. Baseline was defined as mean of steps/day assessed during the week before the randomisation visit.

Time frame:
Week 8
Reported as:
Number · Percent of inactive participants
Percentage of Inactive Patients (Mean of <6000 Steps Per Day) at Week 8
Percent of inactive participantsAB/FF 400/12 μgPlacebo
Percentage of Inactive Patients (Mean of <6000 Steps Per Day) at Week 841.5350.43

Adverse events

Collected over From Screening, Week -2 (Days -17 to -11) to Follow-up, Week 10 (Day 70+3). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AB/FF 400/12 μg—2/134 (1.5%)14/134 (10.4%)
Placebo—3/133 (2.3%)24/133 (18%)
Most frequent serious events
Most frequent serious events
EventAB/FF 400/12 μgPlacebo
Lens dislocationEye disorders0/1341/133
DiverticulitisInfections and infestations0/1341/133
Meniscus injuryInjury, poisoning and procedural complications0/1341/133
FatigueGeneral disorders1/1340/133
Pubis fractureInjury, poisoning and procedural complications1/1340/133
AtaxiaNervous system disorders1/1340/133
Most frequent other events
Most frequent other events
EventAB/FF 400/12 μgPlacebo
NasopharyngitisInfections and infestations14/13413/133
HeadacheNervous system disorders4/13412/133

Baseline characteristics

The Safety Population defined as all randomized patients who took at least one dose of investigational product.

Age, Continuous
Age, Continuous(Years)AB/FF 400/12 μgPlaceboTotal
Mean62.6 ± 7.962.1 ± 7.762.3 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)AB/FF 400/12 μgPlaceboTotal
Female5354107
Male8179160
08

Study locations

26 sites
  • Research Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    Sainte Foy, Quebec G1V 4G5, Canada
  • Research Site
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Berlin, 10717, Germany
  • Research Site
    Berlin, 10787, Germany
  • Research Site
    Berlin, 10969, Germany
  • Research Site
    Berlin, 13086, Germany
  • Research Site
    Dortmund, 44263, Germany
  • Research Site
    Frankfurt, 60596, Germany
  • Research Site
    Großhansdorf, 22927, Germany
  • Research Site
    Hamburg, 20253, Germany
  • Research Site
    Hamburg, 20354, Germany
  • Research Site
    Hannover, 30173, Germany
  • Research Site
    Jena, 7740, Germany
  • Research Site
    Lübeck, 23552, Germany
  • Research Site
    München, 80331, Germany
  • Research Site
    Wiesbaden, 65187, Germany
  • Research Site
    Budapest, 1125, Hungary
  • Research Site
    Deszk, 6772, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Törökbálint, 2045, Hungary
  • Research Site
    Alicante, 03004, Spain
  • Research Site
    Cáceres, 10003, Spain
  • Research Site
    Madrid, 28046, Spain
09

References and documents

Publications

  • Koopman M, Franssen FME, Gaffron S, Watz H, Troosters T, Garcia-Aymerich J, Paggiaro P, Molins E, Moya M, van Burk L, Maier D, Garcia Gil E, Wouters EFM, Vanfleteren LEGW, Spruit MA. Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study. Int J Chron Obstruct Pulmon Dis. 2022 Mar 8;17:517-533. doi: 10.2147/COPD.S308600. eCollection 2022. PubMed 35342289 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Jul 2016, 14 months.

Results were first posted in Oct 2018, 2 years 2 months after primary completion.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 14 months is close to that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2015
First posted
Apr 23, 2015
StartActual
Apr 27, 2015
Primary completionActual
Jul 25, 2016
CompletionActual
Jul 25, 2016
Results first posted
Oct 9, 2018
Last update
Oct 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02424344
Lead sponsor
AstraZeneca
Collaborators
Menarini Group
Responsible party
Sponsor
First posted
Apr 23, 2015
Start date
Apr 27, 2015
Primary completion
Jul 25, 2016
Completion
Jul 25, 2016
Results posted
Oct 9, 2018
Last update
Oct 9, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aclidinium · Formoterol

Start the discussion